ABSTRACT
BACKGROUND: Prenatal exposure to antiseizure medication (ASM) may lead to low plasma folate concentrations and is associated with impaired neurodevelopment. OBJECTIVES: To examine whether maternal genetic liability to folate deficiency interacts with ASM-associated risk of language impairment and autistic traits in children of women with epilepsy. METHODS: We included children of women with and without epilepsy and with available genetic data enrolled in the Norwegian Mother, Father, and Child Cohort Study. Information on ASM use, folic acid supplement use and dose, dietary folate intake, child autistic traits, and child language impairment was obtained from parent-reported questionnaires. Using logistic regression, we examined the interaction between prenatal ASM exposure and maternal genetic liability to folate deficiency expressed as polygenic risk score of low folate concentrations or maternal rs1801133 genotype (CC or CT/TT) on risk of language impairment or autistic traits. RESULTS: We included 96 children of women with ASM-treated epilepsy, 131 children of women with ASM-untreated epilepsy, and 37,249 children of women without epilepsy. The polygenic risk score of low folate concentrations did not interact with the ASM-associated risk of language impairment or autistic traits in ASM-exposed children of women with epilepsy compared with ASM-unexposed children aged 1.5-8 y. ASM-exposed children had increased risk of adverse neurodevelopment regardless of maternal rs1801133 genotype {adjusted odds ratio [aOR] for language impairment aged 8 y was 2.88 [95% confidence interval (CI): 1.00, 8.26] if CC and aOR 2.88 [95% CI: 1.10, 7.53] if CT/TT genotypes}. In children of women without epilepsy aged 3 y, those with maternal rs1801133 CT/TT compared with CC genotype had increased risk of language impairment (aOR: 1.18; 95% CI: 1.05, 1.34). CONCLUSIONS: In this cohort of pregnant women reporting widespread use of folic acid supplements, maternal genetic liability to folate deficiency did not significantly influence the ASM-associated risk of impaired neurodevelopment.
Subject(s)
Autistic Disorder , Epilepsy , Folic Acid Deficiency , Language Development Disorders , Prenatal Exposure Delayed Effects , Humans , Child , Female , Pregnancy , Cohort Studies , Autistic Disorder/genetics , Autistic Disorder/drug therapy , Folic Acid , Epilepsy/drug therapy , Epilepsy/genetics , Folic Acid Deficiency/complications , Folic Acid Deficiency/genetics , Folic Acid Deficiency/drug therapy , Language Development Disorders/drug therapyABSTRACT
BACKGROUND: Tyrosine hydroxylase deficiency (THD) is a rare movement disorder with broad phenotypic expression caused by bi-allelic mutations in the TH gene, which encode for tyrosine hydroxylase (TH) protein. Some patients with THD have improvement in dystonia with carbidopa-levodopa, a synthetic form of dopamine typically used in Parkinson's disease, and are considered to have dopa-responsive THD. THD has been found in 0.5-1 per million persons, although due to overlapping symptoms with other disorders and the need for genetic testing, prevalence is likely underestimated. Existing literature describes some patients with THD having intellectual disability, but comorbid autism spectrum disorder (ASD) has not been reported. CASE PRESENTATION: A nearly 3-year-old boy was referred to pediatric neurology due to hypotonia, delayed motor milestones, and expressive speech delay. Whole exome sequencing confirmed tyrosine hydroxylase deficiency, detecting a novel variant p.S307C first reported here. The child was treated with carbidopa-levodopa with an excellent response, resulting in improved balance, fewer falls, and improved ability to jump, run and climb stairs. He was determined to have dopa-responsive THD. Due to his delays in expressive speech, the boy also had an assessment with a developmental and behavioral pediatrician, who identified a pattern of social pragmatic speech delay, sensory sensitivities, and restricted interests, and determined that he met criteria for a diagnosis of ASD. CONCLUSIONS: While ASD can stand alone as a clinical diagnosis, it is also a cardinal feature of other genetically-based neurological disorders. To our knowledge, this is the first case that describes a patient with both disorders. Perhaps THD may be among the genetic disorders linked with ASD.
Subject(s)
Autism Spectrum Disorder , Autistic Disorder , Language Development Disorders , Child, Preschool , Humans , Male , Carbidopa , Language Development Disorders/drug therapy , Levodopa/therapeutic useABSTRACT
The article provides an analysis of the possibility of neurotrophic therapy of delayed speech development (DSD) in 266 children who underwent dynamic clinical, laboratory, functional and neuropsychological examinations and received neurotrophic therapy. This study confirmed the effectiveness of neurotrophic therapy in the treatment of as isolated speech disorder (ISD) as well speech disorder in the structure of the general psychomotor developmental delay (PDD). The lack of effect in the use of neuroprotective therapy in every sixth child of the latter group can be a marker for the individualization of the treatment of each individual with an emphasis on non-drug rehabilitation methods. The use of cortexin in monotherapy in the treatment of delayed speech development is justified not only by its effectiveness in improving speech development and good tolerance, but also in connection with an improvement in behavior in children of the studied groups, which is possibly associated with a positive effect on mental activity in general, and on self-control function in particular.
Subject(s)
Language Development Disorders , Speech , Child , Humans , Language Development Disorders/drug therapy , Neuropsychological Tests , Speech Disorders/drug therapy , Speech TherapyABSTRACT
49,XXXXY was previously associated with profound to severe intellectual deficits. However, prior research papers on the cognitive profiles of this population were confounded by small samples sizes, wide age spreads, and incomplete histories of testosterone replacement therapy. This study is the first comprehensive, international investigation of the neurocognitive aspects of 49,XXXXY, and the potential effects of biological treatment on this profile. Sixty-seven boys from infancy to 11 years of age were enrolled in this longitudinal study, with the majority of boys postnatally diagnosed though chromosomal analysis. These boys received a comprehensive neurocognitive evaluation tailored to specific language-based deficits and cognitive challenges. Results revealed higher neurocognitive capacities, both verbally and nonverbally, than previously reported in this disorder. Infant boys with 49,XXXXY who received early hormonal therapy (EHT) had significantly higher scores on the cognitive domain of the Bayley Scales of Infant Development than untreated infants (p = .013). In addition, treated school-aged participants had significantly better scaled scores than untreated boys in form completion (p = .042), a task that requires deductive reasoning, on nonverbal testing on the Leiter International Performance Scales. This study indicates greater cognitive capacities with a wide range of abilities in the child with 49,XXXXY, thus warranting further investigation to identify and understand the critical influences on the etiology and the variability of those capacities.
Subject(s)
Cognition Disorders/drug therapy , Klinefelter Syndrome/drug therapy , Language Development Disorders/drug therapy , Neurocognitive Disorders/drug therapy , Aneuploidy , Child , Child, Preschool , Chromosomes, Human, X/genetics , Chromosomes, Human, Y/genetics , Cognition Disorders/complications , Cognition Disorders/genetics , Cognition Disorders/physiopathology , Hormone Replacement Therapy , Humans , Infant , Infant, Newborn , Klinefelter Syndrome/complications , Klinefelter Syndrome/genetics , Klinefelter Syndrome/physiopathology , Language Development Disorders/complications , Language Development Disorders/genetics , Language Development Disorders/physiopathology , Longitudinal Studies , Male , Neurocognitive Disorders/complications , Neurocognitive Disorders/genetics , Neurocognitive Disorders/physiopathologyABSTRACT
We describe the first child with guanidinoacetate methyltransferase (GAMT) deficiency who developed neuroleptic malignant syndrome (NMS) after the treatment of risperidone without elevated creatine kinase (CK) levels. The patient presented with lethargy, hyperthermia, generalized tremor and rigidity with normal serum CK levels. After cessation of risperidone and adding clonezepam to the supportive treatment, symptoms of NMS were ameliorated. We conclude that although serum CK elevation is a useful indicator for the early detection of NMS, normal serum CK levels may be seen during the NMS course in the presence of GAMT deficiency.
Subject(s)
Creatine Kinase/blood , Dopamine Antagonists/adverse effects , Guanidinoacetate N-Methyltransferase/deficiency , Language Development Disorders/drug therapy , Movement Disorders/congenital , Neuroleptic Malignant Syndrome/blood , Risperidone/adverse effects , Child , Humans , Male , Movement Disorders/drug therapy , Neuroleptic Malignant Syndrome/diagnosisABSTRACT
AIM: To study the therapeutic efficacy of peptidergic nootropic medication Cortexin during two-month follow-up in children with developmental dysphasia aged 3-4 years. MATERIAL AND METHODS: Fifty-four children with developmental dysphasia were randomized into two equal groups. The cortexin group received the drug once daily intramuscularly during 10 days. After this course, children did not receive any pharmacotherapy and were examined two months after the beginning of treatment. The control group did not receive pharmacotherapy and was examined twice in two months interval. All the parents were provided with recommendations for the stimulation of speech development in dysphasic children. Before treatment and two months later, speech development was assessed by special scales and questionnaires for parents. RESULTS AND CONCLUSION: After treatment with Cortexin, a significant improvement was achieved not only on the 'expressive language' scale but also on the 'attention to speech' and 'impressive language' scales. The volume of active vocabulary was increased by 2.3 times, the number of articulated phrases by 3.6 times. The evaluation of parents' questionnaires demonstrated the decrease of cerebrasthenic, psychosomatic problems, motor clumsiness, hyperactivity, attention deficit and problems with emotional control in children. The therapy contributed to the reduction of difficulties in communication and social adaptation. The positive effect of Cortexin was observed after the completion of treatment (the protracted effect).
Subject(s)
Aphasia , Language Development Disorders , Nootropic Agents , Aphasia/complications , Aphasia/drug therapy , Attention Deficit Disorder with Hyperactivity/complications , Child , Child, Preschool , Humans , Language Development Disorders/complications , Language Development Disorders/drug therapy , Nootropic Agents/therapeutic use , Parents , SpeechABSTRACT
Recent technological advances in exome sequencing or targeted gene sequencing with epilepsy panels have allowed clinicians to better understand the pathogenesis and clinical presentation of children with epilepsy. We present a child with a SLC6A1 mutation with language delay and autistic spectrum disorder and remind the reader that the identification of specific mutations in these conditions increase the likelihood of identification of potential therapeutic targets.
Subject(s)
Epilepsy/genetics , GABA Plasma Membrane Transport Proteins/genetics , Language Development Disorders/genetics , Mutation , Brain/diagnostic imaging , Brain/physiopathology , Child, Preschool , Diagnosis, Differential , Epilepsy/diagnostic imaging , Epilepsy/drug therapy , Epilepsy/physiopathology , Female , Humans , Language Development Disorders/diagnostic imaging , Language Development Disorders/drug therapy , Language Development Disorders/physiopathologyABSTRACT
We sought to determine whether high-dose folinic acid improves verbal communication in children with non-syndromic autism spectrum disorder (ASD) and language impairment in a double-blind placebo control setting. Forty-eight children (mean age 7 years 4 months; 82% male) with ASD and language impairment were randomized to receive 12 weeks of high-dose folinic acid (2 mg kg-1 per day, maximum 50 mg per day; n=23) or placebo (n=25). Children were subtyped by glutathione and folate receptor-α autoantibody (FRAA) status. Improvement in verbal communication, as measured by a ability-appropriate standardized instrument, was significantly greater in participants receiving folinic acid as compared with those receiving placebo, resulting in an effect of 5.7 (1.0,10.4) standardized points with a medium-to-large effect size (Cohen's d=0.70). FRAA status was predictive of response to treatment. For FRAA-positive participants, improvement in verbal communication was significantly greater in those receiving folinic acid as compared with those receiving placebo, resulting in an effect of 7.3 (1.4,13.2) standardized points with a large effect size (Cohen's d=0.91), indicating that folinic acid treatment may be more efficacious in children with ASD who are FRAA positive. Improvements in subscales of the Vineland Adaptive Behavior Scale, the Aberrant Behavior Checklist, the Autism Symptom Questionnaire and the Behavioral Assessment System for Children were significantly greater in the folinic acid group as compared with the placebo group. There was no significant difference in adverse effects between treatment groups. Thus, in this small trial of children with non-syndromic ASD and language impairment, treatment with high-dose folinic acid for 12 weeks resulted in improvement in verbal communication as compared with placebo, particularly in those participants who were positive for FRAAs.
Subject(s)
Leucovorin/pharmacology , Verbal Behavior/drug effects , Autism Spectrum Disorder/drug therapy , Autistic Disorder/drug therapy , Child , Child Development Disorders, Pervasive/drug therapy , Child, Preschool , Double-Blind Method , Female , Folate Receptor 1/metabolism , Humans , Language Development Disorders/drug therapy , Language Disorders/drug therapy , Leucovorin/metabolism , Male , Placebo Effect , Receptors, Peptide/metabolism , Treatment OutcomeABSTRACT
OBJECTIVE: Evaluate the effects of therapy with citalopram on the central auditory processing in the elderly measured by central auditory tests. STUDY DESIGN: Prospective, randomized, double-blind, placebo-controlled study. SETTING: Tertiary referral center. PATIENTS: Thirty-nine patients older than 60 years with normal hearing thresholds or symmetrical sensorineural hearing loss up to 70 dBHL, word-recognition score equal to or better than 70%, and diagnosed with central auditory processing disorders completed the study. They underwent the mini-mental state examination, as a way to screen those with the possibility of dementia; they also underwent the Beck depression inventory, for screening individuals with depression. INTERVENTION: Citalopram 20âmg/d or placebo for 6 months. MAIN OUTCOME MEASURE: The central auditory tests were applied to the selection of individuals with auditory processing disorders and repeated after 6 months' treatment. The tests were sound localization, speech in noise, dichotic digits test, pitch pattern sequence, duration pattern test, and gaps-in-noise. RESULTS: Comparisons of central auditory tests pre- and posttreatment in groups showed: sound localization (pâ=â0.022), pitch pattern sequence humming (pâ=â0.110), pitch pattern sequence nomination (pâ=â0.355), duration pattern test humming (pâ=â0.801), duration pattern test nomination (pâ=â0.614), and gaps-in-noise (pâ=â0.230). Dichotic tests in right and left ears respectively: speech in noise (pâ=â0.949; pâ=â0.722), dichotic digits test (pâ=â0.943; pâ=â0.513). CONCLUSION: There was no clinical effect with the use of citalopram in central auditory processing tests of the subjects.
Subject(s)
Citalopram/therapeutic use , Hearing Loss, Sensorineural/drug therapy , Language Development Disorders/drug therapy , Neurotransmitter Agents/therapeutic use , Selective Serotonin Reuptake Inhibitors/therapeutic use , Age Factors , Aged , Aged, 80 and over , Double-Blind Method , Female , Hearing Tests , Humans , Male , Prospective Studies , Sound Localization/drug effectsABSTRACT
Guanidinoacetate methyltransferase (GAMT) deficiency is a rare inherited disorder characterized by creatine (Cr) depletion and guanidinoacetate (GAA) accumulation in body fluids. We report the first identified Chinese case, diagnosed in a 4-year-old girl with onset of global developmental. Low Cr and high GAA levels were detected in her serum and urine, and low Cr level in her brain. Compound heterozygous variants in GAMT gene were found, including a previously reported variant at c.491dupG which was inherited from her mother and a novel variant at c.564G>T, which was inherited from her father. The Cr and GAA levels returned back to normal after 3 months of treatment. After one year of treatment, the patient stopped taking antiepileptic drugs and her electroencephalogram (EEG) was also back to normal. The girl was followed up for five years and exhibited good results beyond our expectation. The results have shown that protein restriction with high-dose ornithine and creatine supplements have strong therapeutic potential for our patient.
Subject(s)
Guanidinoacetate N-Methyltransferase/deficiency , Language Development Disorders/drug therapy , Language Development Disorders/genetics , Movement Disorders/congenital , Child, Preschool , Creatine/pharmacology , Creatine/therapeutic use , Dose-Response Relationship, Drug , Female , Follow-Up Studies , Guanidinoacetate N-Methyltransferase/genetics , Guanidinoacetate N-Methyltransferase/metabolism , Humans , Language Development Disorders/enzymology , Movement Disorders/drug therapy , Movement Disorders/enzymology , Movement Disorders/genetics , Ornithine/pharmacology , Ornithine/therapeutic use , Treatment OutcomeABSTRACT
The author considers causes, clinical variants and diagnostic principles of speech development in children. A role of neurobiological factors in the genesis of speech disorders and developmental dysphasia including early organic CNS lesions due to perinatal pathology and hereditary predisposition is described. Outcomes of dysphasia in children reached school-age are discussed. A screening method of the identification of speech delay in early childhood is presented. Early diagnosis and treatment of speech disorders in children are of great importance. Timely treatment with nootropics facilitates the correction of speech disorders.
Subject(s)
Aphasia/diagnosis , Aphasia/drug therapy , Language Development Disorders/diagnosis , Language Development Disorders/drug therapy , Nootropic Agents/therapeutic use , Child , Child, Preschool , Early Diagnosis , Humans , Infant , Mass Screening/methodsABSTRACT
This case report describes the co-occurrence of a psychiatric disorder with a specific communication disorder in a teenage girl who presented to youth mental health services in crisis, posing a significant risk of harm to herself and others. Description of this case would be of interest to practitioners in youth mental health in relation to the assessment and treatment of young people with similar difficulties. We present the case of a 17-year-old girl previously admitted to an inpatient adolescent unit. Her diagnosis was reformulated 4 months into her second admission to include a specific communication disorder with both receptive and expressive difficulties, evident from her pragmatic use of language. She was started on risperidone in month eight; following this, a significant improvement was seen and the patient was discharged a month later. Prior to the start of risperidone, a referral had been made to low secure adolescent services for further assessment and advice on management, due to the patient's challenging presentation and poor engagement with treatment.
Subject(s)
Affective Symptoms/complications , Antipsychotic Agents/therapeutic use , Conduct Disorder/complications , Language Development Disorders/drug therapy , Risperidone/therapeutic use , Speech Disorders/drug therapy , Adolescent , Affective Symptoms/drug therapy , Conduct Disorder/drug therapy , Diagnosis, Differential , Female , Humans , Language Development Disorders/complications , Language Development Disorders/diagnosis , Speech Disorders/complications , Speech Disorders/diagnosis , Treatment OutcomeABSTRACT
UNLABELLED: To study different forms of specific language impairment in children and to evaluate the efficacy of cerebrolysin in clinical and electroencephalographic aspects. MATERIAL AND METHODS: Authors examined 60 children, aged 5-7 years, with a specific language impairment (SLI). RESULTS AND CONCLUSION: The study showed the significantly higher severity of speech disorders, a higher degree of asthenia and dyspraxia/dysgnosia in a group of children with a disorder of receptive language (SLI-R) compared to children with a disorder of expressive speech (SLI-E). A comparative analysis of the EEG power spectra showed large values of slow theta-band EEG in children with SLI compared with healthy children. Children with SLI-R were characterized by the increase in theta rhythm power in the occipital region compared with children with SLI-E. The high efficacy of cerebrolysin in the treatment of this disease (an improvement was obtained in 73.3% of cases) was demonstrated, with the best effect in children with SLI-E (80.0% of cases).
Subject(s)
Amino Acids/therapeutic use , Language Development Disorders/drug therapy , Language Development Disorders/physiopathology , Child , Female , Humans , Language , Male , Occipital Lobe/physiopathology , Speech/physiology , Theta RhythmABSTRACT
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthesis, whereas L-arginine (Arg) and L-homoarginine (hArg) serve as substrates for NO synthesis. ADMA and other methylated arginines are generally believed to exclusively derive from guanidine (N (G))-methylated arginine residues in proteins by protein arginine methyltransferases (PRMTs) that use S-adenosylmethionine (SAM) as the methyl donor. L-Lysine is known for decades as a precursor for hArg, but only recent studies indicate that arginine:glycine amidinotransferase (AGAT) is responsible for the synthesis of hArg. AGAT catalyzes the formation of guanidinoacetate (GAA) that is methylated to creatine by guanidinoacetate methyltransferase (GAMT) which also uses SAM. The aim of the present study was to learn more about the mechanisms of ADMA and hArg formation in humans. Especially, we hypothesized that ADMA is produced by N (G)-methylation of free Arg in addition to the known PRMTs-involving mechanism. In knockout mouse models of AGAT- and GAMT-deficiency, we investigated the contribution of these enzymes to hArg synthesis. Arg infusion (0.5 g/kg, 30 min) in children (n = 11) and ingestion of high-fat protein meals by overweight men (n = 10) were used to study acute effects on ADMA and hArg synthesis. Daily Arg ingestion (10 g) or placebo for 3 or 6 months by patients suffering from peripheral arterial occlusive disease (PAOD, n = 20) or coronary artery disease (CAD, n = 30) was used to study chronic effects of Arg on ADMA synthesis. Mass spectrometric methods were used to measure all biochemical parameters in plasma and urine samples. In mice, AGAT but not GAMT was found to contribute to plasma hArg, while ADMA synthesis was independent of AGAT and GAMT. Arg infusion acutely increased plasma Arg, hArg and ADMA concentrations, but decreased the plasma hArg/ADMA ratio. High-fat protein meals acutely increased plasma Arg, hArg, ADMA concentrations, as well as the plasma hArg/ADMA ratio. In the PAOD and CAD studies, plasma Arg concentration increased in the verum compared to the placebo groups. Plasma ADMA concentration increased only in the PAOD patients who received Arg. Our study suggests that in humans a minor fraction of free Arg is rapidly metabolized to ADMA and hArg. In mice, GAMT and N (G)-methyltransferases contribute to ADMA and hArg synthesis from Arg, whereas AGAT is involved in the synthesis of hArg but not of ADMA. The underlying biochemical mechanisms remain still elusive.
Subject(s)
Arginine/analogs & derivatives , Arginine/administration & dosage , Coronary Artery Disease/blood , Homoarginine/biosynthesis , Peripheral Arterial Disease/blood , Adolescent , Adult , Amidinotransferases/blood , Amidinotransferases/deficiency , Amidinotransferases/genetics , Amidinotransferases/metabolism , Amino Acid Metabolism, Inborn Errors/blood , Amino Acid Metabolism, Inborn Errors/drug therapy , Amino Acid Metabolism, Inborn Errors/genetics , Animals , Arginine/biosynthesis , Child , Coronary Artery Disease/drug therapy , Coronary Artery Disease/genetics , Developmental Disabilities/blood , Developmental Disabilities/drug therapy , Developmental Disabilities/genetics , Female , Guanidinoacetate N-Methyltransferase/blood , Guanidinoacetate N-Methyltransferase/deficiency , Guanidinoacetate N-Methyltransferase/genetics , Guanidinoacetate N-Methyltransferase/metabolism , Humans , Intellectual Disability/blood , Intellectual Disability/drug therapy , Intellectual Disability/genetics , Language Development Disorders/blood , Language Development Disorders/drug therapy , Language Development Disorders/genetics , Male , Mice , Mice, Knockout , Middle Aged , Movement Disorders/blood , Movement Disorders/congenital , Movement Disorders/drug therapy , Movement Disorders/genetics , Peripheral Arterial Disease/drug therapy , Peripheral Arterial Disease/genetics , Speech Disorders/blood , Speech Disorders/drug therapy , Speech Disorders/geneticsABSTRACT
Primary care pediatricians and a variety of specialist physicians strive to define an accurate diagnosis for children presenting with impairment of expressive speech and delay in achieving developmental milestones. Within the past two decades, a group of disorders featuring this presentation have been identified as cerebral creatine deficiency syndromes (CCDS). Patients with these disorders were initially discerned using proton magnetic resonance spectroscopy of the brain within a magnetic resonance imaging (MRI) examination. The objective of this review is to provide the clinician with an overview of the current information available on identifying and treating these conditions. We explain the salient features of creatine metabolism, synthesis, and transport required for normal development. We propose diagnostic approaches for confirming a CCDS diagnosis. Finally, we describe treatment approaches for managing patients with these conditions.
Subject(s)
Amidinotransferases/deficiency , Amino Acid Metabolism, Inborn Errors/diagnosis , Amino Acid Metabolism, Inborn Errors/epidemiology , Brain Diseases, Metabolic, Inborn/diagnosis , Brain Diseases, Metabolic, Inborn/epidemiology , Creatine/biosynthesis , Creatine/deficiency , Guanidinoacetate N-Methyltransferase/deficiency , Intellectual Disability/diagnosis , Intellectual Disability/epidemiology , Language Development Disorders/diagnosis , Language Development Disorders/epidemiology , Mental Retardation, X-Linked/diagnosis , Mental Retardation, X-Linked/epidemiology , Movement Disorders/congenital , Plasma Membrane Neurotransmitter Transport Proteins/deficiency , Speech Disorders/diagnosis , Speech Disorders/epidemiology , Amidinotransferases/genetics , Amino Acid Metabolism, Inborn Errors/drug therapy , Amino Acid Metabolism, Inborn Errors/genetics , Amino Acid Metabolism, Inborn Errors/pathology , Brain Diseases, Metabolic, Inborn/drug therapy , Brain Diseases, Metabolic, Inborn/genetics , Brain Diseases, Metabolic, Inborn/pathology , Creatine/blood , Creatine/genetics , Creatine/physiology , Creatine/urine , Developmental Disabilities/diagnosis , Developmental Disabilities/drug therapy , Developmental Disabilities/epidemiology , Developmental Disabilities/genetics , Developmental Disabilities/pathology , Female , Guanidinoacetate N-Methyltransferase/genetics , Humans , Incidence , Infant , Intellectual Disability/drug therapy , Intellectual Disability/genetics , Intellectual Disability/pathology , Language Development Disorders/drug therapy , Language Development Disorders/etiology , Language Development Disorders/genetics , Language Development Disorders/pathology , Magnetic Resonance Spectroscopy/methods , Male , Mental Retardation, X-Linked/drug therapy , Mental Retardation, X-Linked/genetics , Mental Retardation, X-Linked/pathology , Movement Disorders/diagnosis , Movement Disorders/drug therapy , Movement Disorders/epidemiology , Movement Disorders/genetics , Movement Disorders/pathology , Plasma Membrane Neurotransmitter Transport Proteins/genetics , Sex Factors , Speech Disorders/drug therapy , Speech Disorders/genetics , Speech Disorders/pathology , Utah/epidemiologyABSTRACT
BACKGROUND: Guanidinoacetate methyltransferase deficiency is an autosomal recessively inherited disorder of creatine biosynthesis. We report a new patient with guanidinoacetate methyltransferase deficiency and her >3-year treatment outcome. PATIENT: This is a 6-year-old girl who was diagnosed with guanidinoacetate methyltransferase deficiency at the age of 28 months. She presented with moderate global developmental delay, one afebrile seizure, and hypotonia between 6 and 18 months of life. She was treated with creatine and ornithine supplementation and a strict arginine-restricted diet for 42 months. RESULTS: Mutation analysis (compound heterozygous mutations, a known c.327G>A and a novel c.58dupT [p.Trp20LeufsX65]) and enzyme studies in primary fibroblasts confirmed the diagnosis. After 33 months of therapy, her cerebrospinal fluid guanidinoacetate level decreased from 47 to 5.3 times the normal level. Brain creatine by proton magnetic resonance spectroscopy increased by >75% but did not normalize in the basal ganglia and white matter after 3 years of therapy. Additional treatment with sodium benzoate for 17 months did not further improve plasma guanidinoacetate levels, which questions the relevance of this therapy. CONCLUSION: Treatment did not improve moderate intellectual disability or normalize guanidinoacetate accumulation in the central nervous system.
Subject(s)
Food Preservatives/adverse effects , Guanidinoacetate N-Methyltransferase/deficiency , Language Development Disorders/drug therapy , Movement Disorders/congenital , Sodium Benzoate/adverse effects , Amino Acids/blood , Child , Creatine/administration & dosage , Dietary Supplements , Female , Guanidinoacetate N-Methyltransferase/cerebrospinal fluid , Guanidinoacetate N-Methyltransferase/genetics , Humans , Language Development Disorders/cerebrospinal fluid , Language Development Disorders/genetics , Magnetic Resonance Spectroscopy , Movement Disorders/cerebrospinal fluid , Movement Disorders/drug therapy , Movement Disorders/genetics , Mutation/genetics , Ornithine/administration & dosage , Protons , Psychological Tests , Treatment Failure , Treatment OutcomeABSTRACT
We report a boy, referred at 25 months following a dramatic isolated language regression antedating autistic-like symptomatology. His sleep electroencephalogram (EEG) showed persistent focal epileptiform activity over the left parietal and vertex areas never associated with clinical seizures. He was started on adrenocorticotropic hormone (ACTH) with a significant improvement in language, behavior, and in EEG discharges in rapid eye movement (REM) sleep. Later course was characterized by fluctuations/regressions in language and behavior abilities, in phase with recrudescence of EEG abnormalities prompting additional ACTH courses that led to remarkable decrease in EEG abnormalities, improvement in language, and to a lesser degree, in autistic behavior. The timely documentation of regression episodes suggesting an "atypical" autistic regression, striking therapy-induced improvement, fluctuation of symptomatology over time could be ascribed to recurrent and persisting EEG abnormalities.
Subject(s)
Autistic Disorder/complications , Brain Waves/physiology , Language Development Disorders/complications , Adrenocorticotropic Hormone/therapeutic use , Autistic Disorder/drug therapy , Child, Preschool , Electroencephalography , Hormones/therapeutic use , Humans , Language Development Disorders/drug therapy , Male , Prospective StudiesABSTRACT
OBJECTIVE: To study the efficacy of neurometabolic treatment in dependence of different variants of speech delay (SD), general underdevelopment of speech (GUDS) type, in preschool children. MATERIAL AND METHODS: The study included 130 children, aged 4-6 years, with SD, GUDS type, Most of children were boys (74%). Clinical and psychological characteristics and efficacy of neurorehabilitation were studied in 3 parallel groups. RESULTS AND СONCLUSION: The results demonstrate the heterogeneity of disorders of speech development depending on the clinical and neurological SD variant. Authors have identified characteristics that allow to determine the amount of corrective actions for children with associated pathology and improve rehabilitation actions.
Subject(s)
Adrenergic Uptake Inhibitors/therapeutic use , Language Development Disorders/diagnosis , Language Development Disorders/drug therapy , Nootropic Agents/therapeutic use , Speech Disorders/diagnosis , Speech Disorders/drug therapy , Adrenergic Uptake Inhibitors/administration & dosage , Atomoxetine Hydrochloride , Child , Child, Preschool , Female , Humans , Intercellular Signaling Peptides and Proteins , Male , Nootropic Agents/administration & dosage , Peptides/administration & dosage , Peptides/therapeutic use , Piracetam/administration & dosage , Piracetam/therapeutic use , Propylamines/administration & dosage , Propylamines/therapeutic use , Treatment OutcomeABSTRACT
BACKGROUND: Hyperthyroidism is rare in pre-school children. Untreated, it can have a profound effect on normal growth and development, particularly in the first 2 years of life. Although neurological manifestations of dysthyroid states are well known, specific expressive speech and language disorder as a presentation of hyperthyroidism is rarely documented. METHODS: Case reports of two children with hyperthyroidism presenting with speech and language delay. RESULTS: We report two pre-school children with hyperthyroidism, who presented with expressive speech and language delay, and demonstrated a significant improvement in their language skills following treatment with anti-thyroid medication. CONCLUSIONS: Hyperthyroidism must be considered in all children presenting with speech and language difficulties, particularly expressive speech delay. Prompt recognition and early treatment are likely to improve outcome.
Subject(s)
Hyperthyroidism/complications , Language Development Disorders/etiology , Adrenergic beta-Antagonists/therapeutic use , Carbimazole/therapeutic use , Child, Preschool , Female , Humans , Language Development Disorders/drug therapy , MaleABSTRACT
Developmental dysphasia (alalia) represents a severe speech and language disorder in children. To assess the efficacy of treatment with cerebrolysin, we have examined 60 children with developmental dysphasia, aged from 3 to 4 years. Group 1 (30 patients) received cerebrolysin (monotherapy, daily dosage 0.1 ml/kg, in the morning hours, on each other day, i.m., 30 injections in total) during 2 months. Group 2 (controls, 30 patients) did not receive pharmacotherapy. A significant improvement of expressive, impressive speech and speech attention was observed in group 1 after the treatment. The active vocabulary increased by a factor of 3.5 and phrases number in colloquial speech by a factor of 5, versus 1.5 in the control group. According to parents' questionnaires, the treatment resulted in the decrease of psychasthenic, psychosomatic problems, motor clumsiness and hyperactivity along with the improvement of attention, emotional control and behavioral measures. The positive effect of cerebrolysin on the motor development was demonstrated by the assessment of motor milestones.